Home Protein Tyrosine Kinase EGFR inhibitor Dacomitinib (PF-299804)

solo para uso en investigación

Dacomitinib (PF-299804) HER Inhibitor

Cat. No.: S2727

Dacomitinib is a potent, irreversible pan-ErbB inhibitor, mostly to EGFR with IC50 of 6 nM in a cell-free assay. Dacomitinib inhibits ERBB2 and ERBB4 with IC50 of 45.7 nM and 73.7 nM, respectively. Dacomitinib is effective against NSCLCs with EGFR or ERBB2 mutations as well as those harboring the EGFR T790M mutation. Dacomitinib inhibits cell growth and induces apoptosis. Phase 2.
Dacomitinib (PF-299804) EGFR inhibitor Chemical Structure

Estructura química

Peso molecular: 469.94

Saltar a

Control de calidad (Quality Control)

Lote: Pureza: 99.84%
99.84

Cultivo celular, tratamiento y concentración de trabajo
(Cell Culture, Treatment & Working Concentration)

Líneas celulares Tipo de ensayo Concentración Tiempo de incubación Formulación Descripción de la actividad PMID
PC9 cells Function assay 2 h Inhibition of EGFR exon 19 deletion activating mutant phosphorylation in human PC9 cells after 2 hrs by fluorescence assay, IC50=0.63 nM 23930994
human LoVo cells Function assay 2 h Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay, IC50=0.011 μM 23930994
human NCI-H1975 cells Function assay 2 h Inhibition of EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay, IC50=0.042 μM 23930994
human NCI-H1975 cells Proliferation assay Antiproliferative activity against human NCI-H1975 cells assessed as growth inhibition, GI50=0.1233 μM 26310890
Sf9 Function assay 6 mins Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA, IC50 = 0.006 μM. 27491023
NIH/3T3 Function assay 2 hrs Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins, IC50 = 0.006 μM. 27491023
Sf9 Function assay 6 mins Irreversible inhibition of GST-tagged ERBB2 (unknown origin) (Ile-675 to Val-1256 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA, IC50 = 0.046 μM. 27491023
Sf9 Function assay 6 mins Irreversible inhibition of GST-tagged ERBB4 (unknown origin) (Gly-259 to Gly-690 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA, IC50 = 0.074 μM. 27491023
Sf9 Function assay 30 mins Irreversible inhibition of human recombinant GST-tagged JAK3 expressed in baculovirus infected Sf9 insect cells assessed as reduction in polyglutamic acid-tyrosine phosphorylation after 30 mins by ELISA, IC50 = 3.57 μM. 27491023
NIH/3T3 Function assay 30 mg/kg 2 days In vivo inhibition of full length human ERBB1 autophosphorylation transfected in NIH/3T3 cells implanted in mouse at 30 mg/kg, po qd for 2 days measured 24 hrs post last dose by Western blot analysis 27491023
insect cells Function assay Inhibition of GST-tagged human EGFR catalytic domain expressed in insect cells, IC50 = 0.006 μM. 28754471
NCI-H1819 Antiproliferative assay 72 hrs Antiproliferative activity against human NCI-H1819 cells expressing wild type HER2 incubated for 72 hrs by MTS assay, IC50 = 0.029 μM. 28754471
insect cells Function assay Inhibition of GST-tagged human HER2 catalytic domain expressed in insect cells, IC50 = 0.0457 μM. 28754471
NCI-H1975 Antiproliferative assay 72 hrs Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M/L858R mutant incubated for 72 hrs by MTS assay, IC50 = 0.44 μM. 28754471
Haga clic para ver más datos experimentales de líneas celulares

Información química, almacenamiento y estabilidad (Chemical Information, Storage & Stability)

Peso molecular 469.94 Fórmula

C24H25ClFN5O2

 Almacenamiento (Desde la fecha de recepción)
Nº CAS 1110813-31-4 Descargar SDF Almacenamiento de soluciones madre

Sinónimos PF299804,PF299 Smiles COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4

Solubilidad (Solubility)

In vitro
Lote:

DMSO : 49 mg/mL (104.26 mM)
(El DMSO contaminado con humedad puede reducir la solubilidad. Usar DMSO fresco y anhidro.)

Ethanol : 15 mg/mL

Water : Insoluble

Calculadora de Molaridad

Masa Concentración Volumen Peso molecular
Calculadora de Dilución Calculadora de Peso Molecular

In vivo
Lote:

Calculadora de formulación in vivo (Solución clara)

Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)

mg/kg g μL

Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Resultados del cálculo:

Concentración de trabajo: mg/ml;

Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.

Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.

Mecanismo de acción (Mechanism of Action)

Targets/IC50/Ki
EGFR
(Cell-free assay)
6.0 nM
ErbB2
(Cell-free assay)
45.7 nM
ErbB4
(Cell-free assay)
73.7 nM
In vitro

PF299804 is a specific inhibitor of the ERBB family of kinases. This compound inhibits EGFR signaling and induces apoptosis in the EGFR T790M-containing H3255 GR cell line. It is effective in -sensitive and NSCLC cell lines. This chemical inhibits the growth of H3255 and HCC827 cells engineered to express EGFR T790M. It inhibits EGFR phosphorylation in the presence of the T790M mutation. This agent is believed to irreversibly inhibit ERBB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of ERBB family members. It shows significant growth-inhibitory effects in HER2-amplified gastric cancer cells (SNU216, N87), and it has lower 50% inhibitory concentration values compared with other EGFR tyrosine kinase inhibitors, including BIBW-2992, and CI-1033. This inhibitor induces apoptosis and G1 arrest and inhibits phosphorylation of receptors in the HER family and downstream signaling pathways including STAT3, AKT, and extracellular signal-regulated kinases (ERK) in HER2-amplified gastric cancer cells. It also blocks EGFR/HER2, HER2/HER3, and HER3/HER4 heterodimer formation as well as the association of HER3 with p85α in SNU216 cells. A recent research uses forty-seven human breast cancer and immortalized breast epithelial lines to evaluate the inhibition effects of this compound, the results indicate it preferentially inhibits growth of HER-2-amplified breast cancer cell lines than nonamplified lines (RR = 3.39, p < 0.0001). This chemical reduces the phosphorylation of HER2, EGFR, HER4, AKT, and ERK in the majority of sensitive lines. It exerts its anti-proliferative effect through a combined G0/G1 arrest and an induction of apoptosis.

Ensayo de quinasa
Ensayo de quinasa ERBB basado en ELISA
Las proteínas de fusión citoplasmáticas ERBB1, ERBB 2 y ERBB4 se producen clonando la secuencia ERBB1 (Met-668 a Ala-1211), la secuencia ERBB2 (Ile-675 a Val-1256) y la secuencia ERBB4 (Gly-259 a Gly-690) en el vector baculoviral pFastBac mediante PCR. Las proteínas se expresan en células de insecto Sf9 infectadas por baculovirus como proteínas de fusión GST. Las proteínas se purifican mediante cromatografía de afinidad usando perlas de glutatión-sefarosa. La inhibición de la actividad de la tirosina quinasa ERBB se evalúa utilizando un ensayo de receptor tirosina quinasa basado en ELISA. Las reacciones de quinasa (50 mM HEPES, pH 7,4, 125 mM NaCl, 10 mM MgCl2, 100 μM de ortovanadato de sodio, 2 mM de ditiotreitol, 20 μM de ATP, este compuesto o vehículo de control, y 1-5 nM de GST-erbB por 50 μL de mezcla de reacción) se realizan en placas de 96 pocillos recubiertas con 0,25 mg/mL de poli-Glu-Tyr. Las reacciones se incuban durante 6 minutos a temperatura ambiente mientras se agitan. Las reacciones de quinasa se detienen eliminando la mezcla de reacción y, a continuación, los pocillos se lavan con tampón de lavado (0,1 % Tween 20 en PBS). Los residuos de tirosina fosforilados se detectan añadiendo 0,2 μg/mL de anticuerpo antifosfotirosina (Oncogene Ab-4; 50 μL/pocillo) acoplado a peroxidasa de rábano picante (HRP) diluido en PBS que contiene 3 % de BSA y 0,05 % de Tween 20 durante 25 minutos mientras se agitan a temperatura ambiente. Se retira el anticuerpo y las placas se lavan en tampón de lavado. Se añade sustrato de HRP (SureBlue3,3,5,5-tetrametilbencidina o TMB) (50 μL por pocillo) y se incuba durante 10-20 minutos mientras se agita a temperatura ambiente. La reacción de TMB se detiene con la adición de 50 μL de solución de parada (0,09 N H2SO4). La señal se cuantifica midiendo la absorbancia a 450 nm. Los valores de IC50 se determinan para este compuesto utilizando el método del efecto mediano.
In vivo

Orally administered PF299804 effectively inhibits growth of HCC827 Del/T790M xenografts. Low oral administration of this compound (15mg/kg) causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/ or overexpress ERBB family members or contain the double mutation (L858R/T790M) in ERBB1 (EGFR).

Referencias
  • [4] https://pubmed.ncbi.nlm.nih.gov/22761403/

Aplicaciones (Applications)

Métodos Biomarcadores Imágenes PMID
Western blot pEGFR / EGFR / pERK / ERK / pAKT / AKT / p-mTOR / mTOR / pSTAT3 / STAT3
S2727-WB1
24853121
Immunofluorescence LC3
S2727-IF1
28366635
Growth inhibition assay Cell viability
S2727-viability1
28363995

Información del ensayo clínico (Clinical Trial Information)

(datos de https://clinicaltrials.gov, actualizado el 2024-05-22)

Número NCT Reclutamiento Condiciones Patrocinador/Colaboradores Fecha de inicio Fases
NCT06075615 Not yet recruiting
Carcinoma Non-Small-Cell Lung
Pfizer
 September 1 2024 --
NCT06321510 Not yet recruiting
Lung Cancer
Pfizer
 April 1 2024 --
NCT04609319 Active not recruiting
Lung Cancer
Pfizer
 January 23 2021 --
NCT03865446 Completed
Severe Hepatic Impairment
Pfizer
 April 5 2019 Phase 1
NCT02382796 Completed
NSCLC
Pfizer
 July 10 2015 Phase 2
NCT02268747 Unknown status
Skin Squamous Cell Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori Milano
 November 2014 Phase 2

Preguntas frecuentes (Frequently Asked Questions)

Pregunta 1:
I would like to know whether the in vivo formulation you recommend for it is suitable for oral administration?

Respuesta:
S2727 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 10mg/ml is a homogeneous suspension, and it was fine for oral gavage. When preparing the solution, please dissolve it in DMSO clearly first. If it dissolves not readily, please sonicate and warm it at about 45-50℃ for a while to help dissolving. Then add PEG 300 and Tween 80. After they mixed well, dilute with water. Then it will become a homogeneous suspension.